SANTA CLARA, Calif.--(BUSINESS WIRE)--NewCardio, Inc. (OTCBB: NWCI), a cardiac diagnostic and services company, today revealed the results of its second external validation study of QTinno™ (the “NCE2 Study”), its third and largest clinical validation study to date. The study was led by an independent industry leading cardiac safety expert with extensive experience in pharmaceutical clinical trials.
